MTZ Clinical Research
Welcome,         Profile    Billing    Logout  
 2 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Giannini, Maria Benedetta
RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Recruiting
2
94
Europe
RVU120, SEL120
Ryvu Therapeutics SA
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
02/26
09/26
IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Not yet recruiting
N/A
4000
Europe
Registration into the STREAM platform
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
07/32
07/32
Marconi, Giovanni
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting
2
98
Europe
RVU120, SEL120, Venetoclax
Ryvu Therapeutics SA
Acute Myeloid Leukemia
02/26
09/26
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Calendar Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML
Checkmark Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
Dec 2022 - Dec 2022: Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/24
12/24
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
ImmunoGen, Inc., Jazz Pharmaceuticals
Acute Myeloid Leukemia
12/24
12/24
IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Not yet recruiting
N/A
4000
Europe
Registration into the STREAM platform
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
07/32
07/32
Lemasle-Hue, Emilie
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting
2
98
Europe
RVU120, SEL120, Venetoclax
Ryvu Therapeutics SA
Acute Myeloid Leukemia
02/26
09/26
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting
2
210
Europe
Cytarabine and Idarubicin, CPX-315
Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association
Acute Myeloid Leukemia
10/27
10/27
Mądry, Krzysztof
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting
2
98
Europe
RVU120, SEL120, Venetoclax
Ryvu Therapeutics SA
Acute Myeloid Leukemia
02/26
09/26
RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Recruiting
2
94
Europe
RVU120, SEL120
Ryvu Therapeutics SA
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
02/26
09/26
REMARK_001, NCT06243458: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Not yet recruiting
2
41
Europe
RVU120 (SEL120)
GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group
Low Risk Myelodysplastic Syndromes
05/26
05/27

Download Options